IMA is loading

3rd APV Continuous Manufacturing Conference • 3-5 May 2022

The event takes place from 03/05/2022 to 05/05/2022

IMA Active at the 3rd APV Continuous Manufacturing Conference

IMA Active is pleased to sponsor the 3rd APV Continuous Manufacturing Conference, which will be held in Rome (IT), on May 3-5, 2022.

The symposium will bring together pharmaceutical companies end users, suppliers, regulators and academics to to discuss how the adoption of Continuous Manufacturing for both small molecules and biologic products can transform quality, cost and service for the benefit of the patient.

Dedicated presentations and case studies will give the opportunity to learn about:

  • the current activities regarding ICH Q13
  • formulation development approaches
  • PAT & software systems in CM
  • CM in Japan
  • material characteristics
  • continuous coating

During the 5th session dedicated to the presentation of continuous coating case studies, Jola Gorreja, R&D Process Engineer at IMA Active, will held the presentation “The potential of Croma continuous coater”:
The modern pharmaceutical industry is facing the challenge of transition from a traditional manufacturing approach based on batch-wise production to Continuous Manufacturing.

Croma continuous coater brings an innovative technological progress in manufacturing based on modularity and truly continuous film-coating of tablets. Croma enables faster cycle times with great process flexibility, optimized yield and throughput by enhancing sustainability.

Comparing with the traditional batch coating technology Croma provides an extremely efficient process, which allows also easy scale-up. Coating process becomes more efficient: coating time is reduced, as well as the exposure of the tablets to the coating environment, with a significant impact on reducing manufacturing cost.

Discover agenda>>

 

Presentation: The potential of Croma continuous coater

Wednesday, 05 May 2022

Speaker: Jola Gorreja, R&D Process Engineer at IMA Active

 

Get in touch

For any further information,